Senior Clinical Research Associate - EU; Medical Devices

About Anteris® Technologies

Anteris® Technologies is a global structural heart company dedicated to revolutionizing cardiac care. With offices in Minneapolis, MN, US;
Geneva, Switzerland; and Brisbane and Perth, Australia, we have a growing and inclusive team.

Our mission is to forge new frontiers in cardiac care by pioneering science-driven and measurable advancements to restore heart valve patients to healthy function. Transcatheter Aortic Valve Replacement (TAVR) technologies were originally designed for older, high-risk patients. Today, younger, more active patients need a better solution that will not just open and close but restore healthy heart function. We seek to restore healthy blood flow patterns by creating the world’s first biomimetic TAVR valve, DurAVR® THV.

This cutting‑edge valve, incorporating our proprietary ADAPT® anti‑calcification technology, is designed to mimic the natural function of a healthy heart valve.

The Sr. Clinical Research Associate (CRA) will play a key role in the execution of our global pivotal and European trials, ensuring the highest standards of quality and compliance. This role combines CRO and vendor oversight with budget and agreement negotiation and site activation oversight, clinical monitoring and auditing responsibilities, including site visits to verify data accuracy, assess patient safety, and confirm site compliance with regulatory requirements.

At Anteris® Technologies, you’ll join a team committed to improving the lives of patients with aortic stenosis through groundbreaking structural heart solutions. This is an opportunity to make a measurable impact on patient outcomes while shaping the future of heart valve innovation.

Geneva (Switzerland) or remote Europe

• Oversee CRO and vendor activities, while also directly contributing to study start‑up and conduct activities (e.g., site specific ICF review, essential document review, progress tracking).
• Conduct site initiation and (co‑)monitoring visits; train and support site personnel on sponsor and regulatory requirements; lead or participate in investigator meetings; prepare or review detailed visit reports and documentation.
• Serve as sponsor liaison for assigned research institutions, providing guidance and support to research teams from study start up through close out.
• Verify accuracy and completeness of clinical data, source documentation, and regulatory files, ensuring compliance with study protocols, SOPs, GCP, GDPR, local and global regulations.
• Identify, investigate, and resolve discrepancies in study documentation; implement corrective and preventive actions to reduce recurrence.
• Review and maintain Trial Master File (TMF) documentation for audit readiness; ensure alignment with Good Documentation Practices and regulatory expectations (e.g., FDA, ISO
  14155, EU‑MDR).
• Partner with cross‑functional teams to support site activation, enrollment progress, and data cleaning in alignment with study timelines.

• Bachelor’s degree in a scientific or health‑related field.
• 5+ years of clinical site management experience, including prior field monitoring experience.
• Strong background in medical devices required;
  Class III cardiovascular device experience highly preferred.
• Experience collaborating with CROs, core labs, and external vendors.
• Prior involvement in site‑ and sponsor‑level regulatory agency audits (FDA or BIMO experience a plus).
• Strong written and verbal communication skills, with the ability to present clearly to varied audiences.
• Experience in a Cardiac Cath Lab setting highly preferred.
• Demonstrated problem‑solving, critical thinking, and organizational skills, with keen attention to detail.
• Proficiency with MS Office Suite, Adobe, and EDC platforms (e.g., Medidata RAVE, Viedoc); working knowledge of CTMS and eTMF systems.
• Thorough knowledge of GCP, FDA, ISO
  14155, and other relevant regulatory frameworks.
• Clinical research certification (ACRP or SOCRA, CRA/Coordinator certification) preferred.
• Ability to travel up to 50% during activation and early enrollment; ~30% otherwise across Europe.
• Fluent in spoken and…